August 5, 2020 -- Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed a patent that had been exclusively licensed to Bio-Rad by the University of Chicago.
The Court of Appeals also upheld the lower court's finding for $23.9 million in monetary damages, awarding Bio-Rad a 15% royalty on past and future sales, and a permanent injunction against 10x's Single Cell 3' gene expression products, Single Cell assay for transposase accessible chromatin (ATAC)-seq products, and Single Cell V(D)J products that were found to infringe U.S. Patent 8,889,083, Bio-Rad said.
However, the Court of Appeals also withdrew the District Court's injunction with respect to 10x's Linked-Read and copy number variation (CNV) product lines and reversed the District Court's decision on infringement of two other patents asserted by Bio-Rad. The company said that it does not believe these aspects of the decision will have a material impact on the overall result and is evaluating its options for further review.
Copyright © 2020 scienceboard.net